Sana Farooki

Sana Farooki

Auto-generated profile, based on publicly available information

Sana Farooki

Department of Pediatric Hematology/Oncology Charleston Area Medical Center/West Virginia University‐Charleston Division Charleston West Virginia USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EFEllen Fraint
Ellen Fraint
SFSana Farooki
Sana Farooki
EKElizabeth Klein
Elizabeth Klein
AMAudrey Mauguen
Audrey Mauguen
SPSusan E Prockop
Susan E Prockop
NKNancy A. Kernan
Nancy A. Kernan
Poor graft function (PGF) is a life-threatening complication after allogeneic stem cell transplantation (alloSCT). Historically, outcomes of patients with PGF have been very poor, and there are no standardized approaches to treatment. Furthermore, few outcomes after CD34-selected stem cell boost (CD34+SCB) for PGF in pediatric alloSCT recipients have been reported. Here we report on a single center experience with CD34+SCB for PGF after alloSCT in patients treated on the Pediatric Transplant and Cellular Therapy Service at MSK Kids, Memorial Sloan Kettering Cancer Center. A retrospective analysis of patients transplanted for malignant and nonmalignant disorders who received a CD34+SCB between 2008 to 2020 for treatment of PGF defined as the need for granulocyte colony-stimulating factor (G-CSF) and/or packed red blood cell or platelet transfusion support with bone marrow donor chimerism ≥85%. Peripheral blood stem cells from the original donor were the source for CD34+SCB. Durable complete recovery (durable CR) was defined as recovery of peripheral blood counts without recurrent need for G-CSF or transfusion support. The main outcomes of interest were recovery of hematopoiesis and overall survival. Development of graft versus host disease (GVHD) was an additional outcome of interest. Fourteen patients with PGF received a boost. Six patients had no known infection, while 8 patients had PGF associated with an infection. The probability of CR at 60 days was 79% (95% confidence interval [CI], 57%-100%). The overall survival at both 2 and 5 years was 78% (95% CI, 56%-100%). One patient developed GVHD, which was fatal. No other CD34+SCB-related toxicities were observed. While including patients with PGF as recently defined by the American Society for Transplantation and Cellular Therapy, as well as PGF in patients with concomitant infections, we demonstrate that CD34+SCB is safe and can provide for durable trilineage hematopoietic recovery and long-term survival in pediatric patients after alloSCT.

19 November 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SFSana Farooki
Sana Farooki
OOOluwaseun Olaiya
Oluwaseun Olaiya
LTLisa Tarbell
Lisa Tarbell
NCNicholas A. Clark
Nicholas A. Clark
JLJennifer S. Linebarger
Jennifer S. Linebarger
KLKaren Lewing
Karen Lewing

29 August 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
MSMegha Suri
Megha Suri
SWSamantha Weaver
Samantha Weaver
ENEdward Nehus
Edward Nehus
SFSana Farooki
Sana Farooki
MBMohamad Badawi
Mohamad Badawi